Harbour BioMed Partner Solstice Oncology Raises $225M

Shanghai, China, September 10, 2026

Financing Supports Porustobart Clinical Development

The $225 million Series A financing provides Solstice Oncology with substantial capital to progress porustobart through clinical development and expand its investigation across selected oncology indications. The company is focused on developing therapies that can be administered in the neoadjuvant setting, where treatment is given before surgery with the objective of reducing tumor burden, eliminating microscopic disease and potentially improving long-term outcomes. Porustobart is an investigational antibody developed by Harbour BioMed and is designed to target PD-1, an immune checkpoint protein that can suppress T-cell activity against cancer cells. By blocking the PD-1 pathway, the therapy is intended to restore or enhance antitumor immune responses. The candidate is being evaluated as part of a broader effort to determine whether immune checkpoint inhibition before surgery can generate meaningful clinical and pathological responses. The financing will support Solstice Oncology’s efforts to accelerate the development program and generate additional clinical evidence for porustobart. As with other investigational medicines, the ultimate therapeutic benefit will depend on results from appropriately controlled clinical studies and subsequent regulatory review.

Neoadjuvant Immunotherapy Targets Solid Tumors

The neoadjuvant treatment approach has become an increasingly important area of oncology research. Unlike conventional treatment strategies that may administer systemic therapy after surgery, neoadjuvant immunotherapy exposes the tumor to treatment while it remains in the body. Researchers are investigating whether this setting can generate stronger immune responses by allowing the immune system to recognize tumor-associated antigens released from the primary tumor. Porustobart is being developed with this scientific rationale in mind. The therapy’s mechanism involves PD-1 checkpoint blockade, which may enhance T-cell-mediated immune activity against malignant cells. In the neoadjuvant setting, investigators can also evaluate pathological responses in surgically removed tumor tissue, providing an additional measure of how effectively treatment affects the tumor before surgery. The development program is particularly relevant to resectable cancers, where surgery remains an important component of treatment but recurrence can occur because of microscopic residual disease. An effective systemic therapy administered before surgery could potentially address disease beyond the visible tumor and provide information about a patient’s sensitivity to immunotherapy. However, positive biological or pathological responses do not automatically translate into improved overall survival or disease-free survival. These outcomes will require longer-term clinical follow-up.

Harbour BioMed Partnership Strengthens Oncology Pipeline

The financing also strengthens the relationship between Solstice Oncology and Harbour BioMed, which has been developing porustobart as part of its immuno-oncology portfolio. Harbour BioMed has established expertise in antibody discovery and development, while Solstice Oncology is focused on advancing porustobart through clinical development and commercialization opportunities. The new capital could allow the company to broaden clinical development activities, potentially supporting additional trials, patient enrollment and regulatory interactions. Funding at this scale is particularly important for late-stage oncology development, where multicenter clinical studies can require substantial resources and long-term investment. For the broader biopharmaceutical sector, the financing illustrates continued interest in immune checkpoint inhibitors and neoadjuvant cancer treatment. PD-1 and related checkpoint pathways remain major areas of pharmaceutical research, while developers are increasingly evaluating established immunotherapy mechanisms in earlier stages of cancer treatment. Porustobart remains an investigational therapy and is not approved for marketing based on the financing announcement. Future clinical results will be necessary to determine its safety and efficacy and whether the program can support regulatory submissions. The $225 million Series A financing nevertheless provides Solstice Oncology with significant resources to advance the porustobart program and pursue its goal of developing neoadjuvant immunotherapy options for patients with resectable solid tumors. The progress of the program will be closely linked to clinical evidence demonstrating whether pre-surgical PD-1 blockade can translate into meaningful improvements in patient outcomes.

Source: Harbour BioMed, Solstice Oncology press release